JPMorgan Chase & Co. Increases Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

JPMorgan Chase & Co. lifted its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 14.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 12,129 shares of the company’s stock after buying an additional 1,490 shares during the period. JPMorgan Chase & Co.’s holdings in Dianthus Therapeutics were worth $264,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in DNTH. R Squared Ltd purchased a new position in shares of Dianthus Therapeutics in the fourth quarter worth $26,000. KLP Kapitalforvaltning AS purchased a new position in shares of Dianthus Therapeutics in the 4th quarter worth $33,000. KBC Group NV bought a new stake in shares of Dianthus Therapeutics in the fourth quarter worth $35,000. AlphaQuest LLC increased its position in Dianthus Therapeutics by 273.1% during the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock valued at $91,000 after acquiring an additional 3,072 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in Dianthus Therapeutics in the fourth quarter valued at about $201,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on DNTH. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Guggenheim reissued a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $54.33.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $21.70 on Friday. The firm has a market cap of $697.13 million, a price-to-earnings ratio of -8.68 and a beta of 1.48. The firm has a fifty day moving average price of $19.85 and a 200 day moving average price of $22.68. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.37 and a fifty-two week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million. As a group, research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.